AUTL - Company ID 0001730463
Autolus Therapeutics plc trades as AUTL. In its fiscal 2025 annual report the company posted revenue of $75.39M, up 644.9% from the prior year and net income of -$287.53M. This page tracks Autolus Therapeutics plc through 305 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years Autolus Therapeutics plc's revenue grew from $1.21M to $75.39M, a compound annual growth rate of 58.2%. Net profit margin expanded from -1035.5% to -381.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-14 |
| Major company event | 8-K | 2026-05-14 |
| EFFECT | - | 2026-05-05 |
| EFFECT | - | 2026-05-05 |
| Major company event | 8-K | 2026-04-29 |
| Major company event | 8-K | 2026-04-16 |
The largest companies sharing Autolus Therapeutics plc's SEC industry classification (biological products, (no diagnostic substances)).
Autolus Therapeutics plc reported revenue of $75.39M for fiscal year 2025, an increase of 644.9% year over year.
In its latest fiscal year Autolus Therapeutics plc reported a net loss of $287.53M.